01Start with the name used in the actual report

The supplied 5 mg certificate, MA-PEP-0027, names Modified GRF (1–29) and explicitly describes it as a 29-residue amidated peptide marketed as CJC-1295 without DAC. Its identity result is a comparison with a named reference.Supplied Modified GRF (1–29) 5 mg report — MA-PEP-0027, Rev. 01 (opens in a new tab)

The document does not print the full amino-acid sequence. The report name therefore provides a clearer material category than the abbreviated catalogue label, but it does not disclose every structural detail of the reference.

Retain all three fields when collecting literature. Replacing them with CJC-1295 alone removes the information most likely to affect whether a paper is relevant.

02Understand why the added group matters

Jetté and colleagues’ 2005 original study describes CJC-1295 as a substituted GRF-derived peptide with an added reactive lysine derivative at its C terminus. The research examined albumin bioconjugation and prolonged persistence.Jetté and colleagues — Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates: identification of CJC-1295 as a long-lasting GRF analog (opens in a new tab)

This is a structural modification with a purpose in the investigated molecule. Omitting it is not merely changing the packaging, concentration or punctuation in the name.

The FDA’s 2024 technical evaluation also distinguishes CJC-1295-related forms with and without DAC, and separately distinguishes salt forms. Here that source is used for chemical identity distinctions, not as a statement of current UK legal status.FDA — CJC-1295-related substances: December 2024 PCAC briefing document (opens in a new tab)

This separation prevents a misleading comparison in which two materials are treated as equivalent merely because both labels contain the same development code.

03Keep the long-acting human study with its own molecule

Teichman and colleagues’ 2006 publication reports placebo-controlled studies of a long-acting CJC-1295 analogue in healthy adults, measuring pharmacokinetics and growth-hormone/IGF-I responses.Teichman and colleagues — Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GHRH, in healthy adults (opens in a new tab)

That study is relevant background to the development of albumin-binding CJC-1295. It does not provide a measured human duration of action for the Modified GRF material in the supplied without-DAC report.

A common reading error would copy the long-acting study’s time course into a description of the catalogue product. The correct response to the identity mismatch is to exclude that result as a direct duration estimate, not to adjust it using an assumed conversion.

This guide therefore does not assign a numerical half-life to the without-DAC product. A defensible value would need a matching molecular preparation, an identified study and a clear account of what was measured.

The same restriction applies to hormone-response magnitudes. A shared GRF-derived sequence cannot, by itself, transfer a result across materially different experimental agents.

04Sort candidate papers into direct and contextual evidence

This approach leaves room for useful background papers without letting them stand in for missing direct evidence. It also makes uncertainty visible to the next reader instead of hiding it in a familiar name.

For this catalogue entry, the most useful reference question is which precise Modified GRF structure was tested. Resolve that before interpreting duration, response magnitude or claims about a combination containing it.